NZ748483A - Methods for treatment of alport syndrome - Google Patents
Methods for treatment of alport syndromeInfo
- Publication number
- NZ748483A NZ748483A NZ748483A NZ74848313A NZ748483A NZ 748483 A NZ748483 A NZ 748483A NZ 748483 A NZ748483 A NZ 748483A NZ 74848313 A NZ74848313 A NZ 74848313A NZ 748483 A NZ748483 A NZ 748483A
- Authority
- NZ
- New Zealand
- Prior art keywords
- alport syndrome
- modified oligonucleotide
- treatment
- methods
- medicament
- Prior art date
Links
- 208000024985 Alport syndrome Diseases 0.000 title abstract 3
- 208000003215 hereditary nephritis Diseases 0.000 title abstract 3
- 108091034117 Oligonucleotide Proteins 0.000 abstract 5
- 239000003814 drug Substances 0.000 abstract 2
- 239000002777 nucleoside Substances 0.000 abstract 2
- 230000000295 complement effect Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 108091062762 miR-21 stem-loop Proteins 0.000 abstract 1
- 108091041631 miR-21-1 stem-loop Proteins 0.000 abstract 1
- 108091044442 miR-21-2 stem-loop Proteins 0.000 abstract 1
- 150000003833 nucleoside derivatives Chemical class 0.000 abstract 1
- 125000003835 nucleoside group Chemical group 0.000 abstract 1
Abstract
Disclosed is the use of a modified oligonucleotide in the manufacture of a medicament for the treatment of Alport Syndrome in a subject having or suspected of having Alport Syndrome, wherein the modified oligonucleotide consists of 8 to 30 linked nucleosides, wherein the nucleobase sequence of the modified oligonucleotide is complementary to miR-21, and wherein the modified oligonucleotide comprises at least one modified nucleoside, wherein the medicament is to be administered to the subject at a dose of 110 mg of the modified oligonucleotide.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261711514P | 2012-10-09 | 2012-10-09 | |
| US201361779137P | 2013-03-13 | 2013-03-13 | |
| NZ73085613 | 2013-10-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ748483A true NZ748483A (en) | 2023-01-27 |
Family
ID=85323531
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ748483A NZ748483A (en) | 2012-10-09 | 2013-10-08 | Methods for treatment of alport syndrome |
Country Status (1)
| Country | Link |
|---|---|
| NZ (1) | NZ748483A (en) |
-
2013
- 2013-10-08 NZ NZ748483A patent/NZ748483A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ630596A (en) | Methods for treatment of alport syndrome | |
| MX2015005949A (en) | Antiviral azasugar-containing nucleosides. | |
| PH12014501815A1 (en) | Purinone compounds as kinase inhibitors | |
| PH12015500940A1 (en) | Bruton`s tyrosine kinase inhibitors | |
| MX359548B (en) | Modified rnai agents. | |
| NZ702744A (en) | D-amino acid compounds for liver disease | |
| EA201491584A1 (en) | METHODS OF TREATING NON-SMALL-CELL LUNG CANCER WITH THE USE OF COMBINED TREATMENT WITH KINASE TOR INHIBITOR | |
| NZ616512A (en) | Modulation of hepatitis b virus (hbv) expression | |
| MX356210B (en) | Acrylic polymer formulations. | |
| NZ631144A (en) | Compositions and methods for transmucosal absorption | |
| MX2011007589A (en) | Treatment of a cancer using a combination of bendamustine and an anti-cd20 antibody. | |
| MX2011011596A (en) | Perifosine and capecitabine as a combined treatment for cancer. | |
| NZ713868A (en) | Treatment of cancer using coenzyme q10 combination therapies | |
| NZ612717A (en) | Treatment of pain associated with dislocation of basal endometrium | |
| MX348412B (en) | Methods of using sns-595 for treatment of cancer subjects with reduced brca2 activity. | |
| SG179069A1 (en) | Cancer stem cell-targeted and drug resistant cancer therapy | |
| PH12017500617A1 (en) | Dosage regimen for pegylated interferon | |
| NZ748483A (en) | Methods for treatment of alport syndrome | |
| WO2014018763A3 (en) | Method of treating type i diabetes using apolipoprotein aiv | |
| MX2013009456A (en) | Vinyl -aryl - sulfones for use in peritoneal carcinomatosis. | |
| MX2011011879A (en) | Use of betaxanthins and derivatives thereof for the preparation of a drug for the treatment of prediabetes and diabetes. | |
| NZ631362A (en) | Arry-520 for use in treating cancer in a patient with low aag | |
| UA92865C2 (en) | Method for treatment of non-hospital pneumony in patients infected with Chlamydophila pneumoniae, at risk of destabilization of ACCOMPANYING ischemic heart desease | |
| Reissig | Tussive irritation, epistaxis and lassitude in an elderly patient: case report | |
| MX2011011880A (en) | Use of derivatives of betanidine and isobetanidine for the preparation of a drug for the treatment of prediabetes and diabetes. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ASS | Change of ownership |
Owner name: SANOFI, FR Effective date: 20190731 |
|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 6 YEARS UNTIL 08 OCT 2023 BY SPRUSON + FERGUSON PTY LTD Effective date: 20230602 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 OCT 2024 BY CPA GLOBAL Effective date: 20230831 |